



Patrick Archdeacon is a medical officer in the Office of Medical Policy with the Center for Drug Evaluation and Research (CDER) at FDA. His work at the Office of Medical Policy includes involvement in the Clinical Trials Transformation Initiative (a public-private partnership that identifies practices to increase the quality and efficiency of clinical trials) and the Sentinel Initiative (a system that will draw on existing automated healthcare data from multiple sources

to actively monitor the safety of medical products continuously and in real time). Dr Archdeacon originally joined FDA in 2008 as a medical officer in the Division of Special Pathogens and Transplant Products in the Office of New Drugs. He attended medical school at Columbia University's School of Physicians and Surgeons. Prior to joining FDA, he completed his training in internal medicine at the New York Presbyterian Hospital and in nephrology and transplant nephrology at the University of North Carolina.